1.
Blood Adv
; 1(16): 1254-1258, 2017 Jul 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29296765
RESUMO
Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to eculizumab.